Re-evaluation of HER2 status in 606 breast cancers—gene protein assay on tissue microarrays versus routine pathological assessment

Emma Sandén; Somayeh Khazaei; Helga Tryggvadottir; Signe Borgquist; Karolin Isaksson; Karin Jirström; Helena Jernström

doi:10.1007/s00428-020-02768-x

Re-evaluation of HER2 status in 606 breast cancers—gene protein assay on tissue microarrays versus routine pathological assessment

Emma Sandén, Somayeh Khazaei, Helga Tryggvadottir, Signe Borgquist, Karolin Isaksson, Karin Jirström, Helena Jernström

Research output: Contribution to journal › Article › peer-review

Abstract

Human epidermal growth factor receptor 2 (HER2) status in breast cancer is routinely determined through immunohistochemistry (IHC) and/or in situ hybridisation (ISH) performed on whole tissue sections (WS). The purpose was to evaluate whether a gene protein assay (GPA) combining IHC with ISH, performed on breast cancer tissue microarray (TMA), is suitable for large-scale retrospective HER2 status evaluation. TMAs from 606 tumours from a Swedish population-based cohort (2005–2012) were stained with GPA. GPA IHC on TMA yielded weaker staining than IHC on WS during routine pathological assessment (86.0% agreement). However, final HER2 status agreement between GPA on TMA and WS based on both IHC and ISH was 97.7%. Only 14 tumours were discordant and one tumour with IHC score 1+ on both TMA and WS was HER2 amplified on TMA. In conclusion, GPA on TMA is suitable for large-scale retrospective evaluation of HER2 status.

Original language	English
Pages (from-to)	317-320
Number of pages	4
Journal	Virchows Archiv
Volume	477
Issue number	2
Early online date	2020 Feb 20
DOIs	https://doi.org/10.1007/s00428-020-02768-x
Publication status	Published - 2020 Aug

Subject classification (UKÄ)

Cancer and Oncology

Free keywords

Gene protein assay
HER2
Immunohistochemistry
In situ hybridization
Tissue microarray
Whole tissue section

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00428-020-02768-xLicence: CC BY

Cite this

@article{ac6c5c2393b649d792c0b5cbee31f8fc,

title = "Re-evaluation of HER2 status in 606 breast cancers—gene protein assay on tissue microarrays versus routine pathological assessment",

abstract = "Human epidermal growth factor receptor 2 (HER2) status in breast cancer is routinely determined through immunohistochemistry (IHC) and/or in situ hybridisation (ISH) performed on whole tissue sections (WS). The purpose was to evaluate whether a gene protein assay (GPA) combining IHC with ISH, performed on breast cancer tissue microarray (TMA), is suitable for large-scale retrospective HER2 status evaluation. TMAs from 606 tumours from a Swedish population-based cohort (2005–2012) were stained with GPA. GPA IHC on TMA yielded weaker staining than IHC on WS during routine pathological assessment (86.0% agreement). However, final HER2 status agreement between GPA on TMA and WS based on both IHC and ISH was 97.7%. Only 14 tumours were discordant and one tumour with IHC score 1+ on both TMA and WS was HER2 amplified on TMA. In conclusion, GPA on TMA is suitable for large-scale retrospective evaluation of HER2 status.",

keywords = "Gene protein assay, HER2, Immunohistochemistry, In situ hybridization, Tissue microarray, Whole tissue section",

author = "Emma Sand{\'e}n and Somayeh Khazaei and Helga Tryggvadottir and Signe Borgquist and Karolin Isaksson and Karin Jirstr{\"o}m and Helena Jernstr{\"o}m",

year = "2020",

month = aug,

doi = "10.1007/s00428-020-02768-x",

language = "English",

volume = "477",

pages = "317--320",

journal = "Virchows Archiv",

issn = "0945-6317",

publisher = "Springer",

number = "2",

}

TY - JOUR

T1 - Re-evaluation of HER2 status in 606 breast cancers—gene protein assay on tissue microarrays versus routine pathological assessment

AU - Sandén, Emma

AU - Khazaei, Somayeh

AU - Tryggvadottir, Helga

AU - Borgquist, Signe

AU - Isaksson, Karolin

AU - Jirström, Karin

AU - Jernström, Helena

PY - 2020/8

Y1 - 2020/8

N2 - Human epidermal growth factor receptor 2 (HER2) status in breast cancer is routinely determined through immunohistochemistry (IHC) and/or in situ hybridisation (ISH) performed on whole tissue sections (WS). The purpose was to evaluate whether a gene protein assay (GPA) combining IHC with ISH, performed on breast cancer tissue microarray (TMA), is suitable for large-scale retrospective HER2 status evaluation. TMAs from 606 tumours from a Swedish population-based cohort (2005–2012) were stained with GPA. GPA IHC on TMA yielded weaker staining than IHC on WS during routine pathological assessment (86.0% agreement). However, final HER2 status agreement between GPA on TMA and WS based on both IHC and ISH was 97.7%. Only 14 tumours were discordant and one tumour with IHC score 1+ on both TMA and WS was HER2 amplified on TMA. In conclusion, GPA on TMA is suitable for large-scale retrospective evaluation of HER2 status.

AB - Human epidermal growth factor receptor 2 (HER2) status in breast cancer is routinely determined through immunohistochemistry (IHC) and/or in situ hybridisation (ISH) performed on whole tissue sections (WS). The purpose was to evaluate whether a gene protein assay (GPA) combining IHC with ISH, performed on breast cancer tissue microarray (TMA), is suitable for large-scale retrospective HER2 status evaluation. TMAs from 606 tumours from a Swedish population-based cohort (2005–2012) were stained with GPA. GPA IHC on TMA yielded weaker staining than IHC on WS during routine pathological assessment (86.0% agreement). However, final HER2 status agreement between GPA on TMA and WS based on both IHC and ISH was 97.7%. Only 14 tumours were discordant and one tumour with IHC score 1+ on both TMA and WS was HER2 amplified on TMA. In conclusion, GPA on TMA is suitable for large-scale retrospective evaluation of HER2 status.

KW - Gene protein assay

KW - HER2

KW - Immunohistochemistry

KW - In situ hybridization

KW - Tissue microarray

KW - Whole tissue section

U2 - 10.1007/s00428-020-02768-x

DO - 10.1007/s00428-020-02768-x

M3 - Article

C2 - 32080761

AN - SCOPUS:85079822812

SN - 0945-6317

VL - 477

SP - 317

EP - 320

JO - Virchows Archiv

JF - Virchows Archiv

IS - 2

ER -

Re-evaluation of HER2 status in 606 breast cancers—gene protein assay on tissue microarrays versus routine pathological assessment

Abstract

Subject classification (UKÄ)

Free keywords

UN SDGs

Access to Document

Fingerprint

Cite this